Ranbaxy Gets Nod For Biaxin Generic

Ranbaxy Laboratories has received final approval from the US Food and Drug Administration to make and sell generic version of Abbott's anti-infective Biaxin. The approval is for two strengths of Clarithromycin for Oral Suspension, USP. The company said in a statement that it was the first to have been granted a generic approval for the Oral Suspension form along with Clarithromycin tablets. The total annual sales for the drug were $99.7 million with suspension sales totalling $25.3 million.